GT Biopharma (GTBP) Total Non-Current Liabilities (2013 - 2024)
GT Biopharma (GTBP) posted quarterly Total Non-Current Liabilities of -$277000.0 for Q2 2024, down 105.72% year-over-year from $4.8 million in Q3 2023, and down 106.59% quarter-over-quarter from $4.2 million in Q1 2024.
GT Biopharma (GTBP) Total Non-Current Liabilities (2013 - 2024) Analysis & Trends
GT Biopharma (GTBP) has reported Total Non-Current Liabilities for 8 consecutive years, with -$277000.0 the latest figure, recorded in Q2 2024.
- In Q2 2024, Total Non-Current Liabilities fell 105.72% year-over-year to -$277000.0; the TTM figure through Jun 2024 stood at -$277000.0 (down 105.72% YoY), while the FY2023 annual figure was $5.6 million, up 12.0% from the prior year.
- Total Non-Current Liabilities retreated to -$277000.0 in Q2 2024 per GTBP's latest filing, from $4.2 million in the prior quarter.
- Across five years, Total Non-Current Liabilities topped out at $5.6 million in Q4 2023 and bottomed at -$277000.0 in Q2 2024.
- Historically, Total Non-Current Liabilities has averaged $4.1 million across 3 years, with a median of $4.8 million in 2023.
- Annual changes were most pronounced in 2023 — Total Non-Current Liabilities increased 12.0% — and 2024, when it plunged 105.72%.
- GT Biopharma's Total Non-Current Liabilities stood at $5.0 million in 2022, then gained by 12.0% to $5.6 million in 2023, then plunged by 104.96% to -$277000.0 in 2024.
- Business Quant data shows GTBP's Total Non-Current Liabilities at -$277000.0 in Q2 2024, $4.2 million in Q1 2024, and $5.6 million in Q4 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 5.92 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 7.74 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 40.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 3.92 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 1.88 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 4.20 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 724.15 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 1.17 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 9.32 Bn |
| 10 | GT Biopharma | 8.64 Mn | 8.64 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2024 | -277,000.00 |
| Mar 31, 2024 | 4.21 Mn |
| Dec 31, 2023 | 5.58 Mn |
| Sep 30, 2023 | 5.04 Mn |
| Jun 30, 2023 | 4.84 Mn |
| Mar 31, 2023 | 4.11 Mn |
| Dec 31, 2022 | 4.98 Mn |
| Mar 31, 2017 | 18.35 Mn |
| Sep 30, 2016 | 400,000.00 |
| Jun 30, 2016 | 528,000.00 |
| Mar 31, 2016 | 553,000.00 |
| Dec 31, 2015 | 714,000.00 |
| Dec 31, 2014 | 634,000.00 |
| Mar 31, 2014 | 128,000.00 |
| Dec 31, 2013 | 97,000.00 |